Peter Anderson, Ph.D.

Pilot Pharmacokinetics Lead

University of Colorado – Denver

Dr. Peter L. Anderson is a Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, where he serves as Director of the Colorado Antiviral Pharmacology Bioanalytical Laboratory, the Center for Translational Pharmacokinetics and Pharmacogenomics, and the Pharmaceutical Sciences Graduate Program. With more than twenty-five years of experience as a principal investigator, he has led a sustained and highly productive research program in antiviral clinical pharmacology. Dr. Anderson’s laboratory has provided core bioanalytical and pharmacology support for numerous NIH-funded national trial networks, including the AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), and the HIV Prevention Trials Network (HPTN). His contributions have shaped the field of HIV prevention and treatment, including the development and validation of key bioanalytical methodologies that informed FDA-approved indications for antiretroviral-based HIV prevention strategies. A recognized leader in antiviral translational sciences, Dr. Anderson has made lasting impacts on pharmacokinetic–pharmacodynamic modeling, drug adherence assessment, and the clinical translation of long-acting antiviral therapies. His research program continues to focus on optimizing antiretroviral drug delivery, exposure biomarkers, and prevention strategies across diverse patient populations. Dr. Anderson is also deeply committed to education and mentorship. He has received multiple awards for teaching and graduate training and has successfully mentored Ph.D. students, postdoctoral researchers, and junior faculty members who have gone on to secure independent funding and establish their own research programs. His commitment to developing the next generation of scientists parallels his leadership in advancing antiviral pharmacology to improve public health worldwide.